Zonisamide improves wearing‐off in Parkinson's disease: A randomized, double‐blind study

Murata, Miho; Hasegawa, Kazuko; Kanazawa, Ichiro; Fukasaka, Junichi; Kochi, Kenji; Shimazu, Rieko

doi:10.1002/mds.26286

Cited by 101 publications

(108 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no new safety concerns. Zonisamide, a mixed MAO‐B inhibitor; channel blocker, and glutamate release inhibitor, was evaluated in 1 new high‐quality study; the efficacy conclusion was changed to “efficacious, ” and the new practice implication is “clinically useful.” There are no new safety concerns. Safinamide was evaluated in 2 high‐quality studies (1 with an 18‐month placebo‐controlled extension), leading to the conclusion of “efficacious ” and the practice implication of “clinically useful.” There were no safety concerns.…”

Section: Results and Conclusionmentioning

confidence: 99%

International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Results and Conclusionmentioning

confidence: 99%

International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In 2009, zonisamide was approved for the treatment of PD in Japan. The precise sites of action have remained largely unknown, but zonisamide has multiple actions, including inhibition of sodium channels, T‐type calcium channels, monoamine oxidase‐B activity, activation of dopamine synthesis, and dopamine release (Murata et al., 2015). In a recent study, zonisamide enhanced novelty‐seeking behavior in rats (Uemura, Asano, Hikawa, Yamakado, & Takahashi, 2017).…”

Section: Discussionmentioning

confidence: 99%

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

IntroductionImpulse control behaviors (ICBs) are impulsive–compulsive behaviors often associated with dopamine replacement therapy in Parkinson's disease (PD). Although remission can occur in ICB, only four reports on the ratio of remission and the persistence of ICB have been published, and the associated factors with ICB remission or persistence have been little known. Therefore, we conducted a longitudinal assessment of the remission, persistence, and development of ICB and those associated factors in patients with PD.MethodsWe retrospectively investigated a PD database at Aomori Prefectural Central Hospital, Japan. One hundred and forty‐eight patients with PD who could be followed up for 2 years were enrolled. ICB was assessed using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson's disease. Motor severity (Hoehn and Yahr scale and United Parkinson's Disease Rating Scale), cognitive function (Mini–Mental State Examination), and other clinical variables (sex, age, onset age, disease duration, olfactory dysfunction, and dyskinesia) and medications used to treat PD were assessed. Univariate analyses were performed.ResultsSeven patients were excluded because of the exclusion criteria, and 141 patients were analyzed. Thirty patients (21.3%) had ICB at baseline, and these patients also had significantly higher use of pergolide. The ICB remission rate was 60%, the ICB persistence ratio was 40%, and the ICB development ratio was 12.6% over 2 years. Statistically, younger age and pergolide use were associated with ICB persistence. Being male, having dyskinesia, and rotigotine, entacapone, zonisamide, and istradefylline use were associated with ICB development.ConclusionThis study suggests that younger age and pergolide use may be the new associated factors with ICB persistence and that entacapone, zonisamide, and istradefylline use may be associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB.

show abstract

“…Furthermore, some patients receiving the 50 mg dose showed a reduction in troublesome dyskinesias. A recent report also showed significantly decreased OFF-state with no increase in dyskinesia, in the zonisamide group compared to placebo [48].…”

Section: Antiepilepticsmentioning

confidence: 93%

Emerging drugs for levodopa-induced dyskinesia

Dakheel

Beaulieu‐Boire

Fox

2014

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

Zonisamide improves wearing‐off in Parkinson's disease: A randomized, double‐blind study

Abstract: The study provides evidence that confirms the efficacy of zonisamide 50 mg/d for reduction in "off" time in PD patients with wearing-off phenomena.

Cited by 101 publications

References 24 publications

International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

Emerging drugs for levodopa-induced dyskinesia

Contact Info

Product

Resources

About